Table 2.
Demographic data of malignant brain tumor patients (n = 110)
| Group | 1 |
2 |
3 |
4 |
|
|---|---|---|---|---|---|
| No. of Patients (%) | No. of Patients (%) | No. of Patients (%) | No. of Patients (%) | ||
| Sex |
Male | 31(64.58) | 20 (58.82) | 13 (76.47) | 7 (63.63) |
| Female |
17 (35.41) |
14 (41.17) |
4 (23.52) |
4 (36.36) |
|
| Age (in years) |
<16 | 4 (8.33) | 4 (11.76) | 4 (23.52) | 2 (18.18) |
| 16–40 | 13 (11.81) | 11 (10) | 9 (8.18) | 9 (8.18) | |
| 41–60 | 19 (17.27) | 16 (14.55) | 3 (2.72) | 0 | |
| >60 |
12 (10.9) |
3 (2.72) |
1 (0.91) |
0 |
|
| Grade |
I | 1 (2.08) | 1 (2.94) | 0 | 0 |
| II | 9 (18.75) | 3 (8.82) | 4 (23.52) | 3 (27.27) | |
| III | 9 (18.75) | 9 (26.47) | 6 (35.29) | 6 (54.54) | |
| IV | 27 (56.25) | 20 (5.88) | 7 (41.17) | 2 (4.16) | |
| Not Known |
2 (4.16) |
1 (2.94) |
0 |
0 |
|
| Type of tumour |
Glial cell tumorsb | 38 (79.16) | 30 (88.23) | 12 (70.58) | 11 (100) |
| Embryonal tumorsc | 2 (4.17) | 2 (5.88) | 3 (17.64) | 0 | |
| Tumors of pineal regiond | 0 | 0 | 1 (5.88) | 0 | |
| Ependymoma | 0 | 1 (2.94) | 0 | 0 | |
| Meningioma | 2 (4.17) | 0 | 1 (5.88) | 0 | |
| DNA |
6 (12.5) |
1 (2.94) |
0 |
0 |
|
| Conventional treatment |
Only SU | 2 (1.81) | 0 | 0 | 0 |
| Only RT | 5 (4.54) | 1 (0.9) | 0 | 1(0.9) | |
| SU + RT | 14 (12.72) | 6 (5.45) | 3 (2.72) | 5 (4.54) | |
| RT + CH | 3 (2.72) | 3 (2.72) | 2 (1.81) | – | |
| SU + RT + C– CH | 24 (21.81) | 24 (21.81) | 11 (10) | 5 (4.54) | |
| No Treatment |
0 |
0 |
1 (0.9) |
0 |
|
| Molecular analysisa | IDH 1/2 (R132H) |
P-1 (6.66) N-2 (13.33) |
P- 1 (8.33) N- 4 (33.33) |
P- 1 (16.66) |
P- 3 (75) |
| 1p/19q codeletion |
N- 3 (20) |
N- 2 (16.66) |
- |
P- 1 (25) N- 1 (25) |
|
| 1p deletion |
P- 2 (13.33) N- 1 (6.66) |
- |
- |
- |
|
| 19q deletion |
- |
P-1 (8.33) |
- |
- |
|
| MGMT Promoter |
N- 1 (6.66) |
P- 1 (8.33) |
P- 1 (16.66) |
– |
|
| ATRX loss on function |
P- 3 (20) N- 1 (6.66) |
P- 1(8.33) N- 3 (25) |
P- 1 (16.66) |
P- 0 N- 2 (50) |
|
| EGFR amplification |
N- 1 (6.66) |
– |
– |
P- 1 (25) |
|
| Ki-67 |
N- 1 (6.66) |
P- 1 (8.33) |
P- 3 (50) |
N- 1 (25) |
|
| p53 |
P- 5 (33.33) |
P- 8 (66.67) N- 1 (8.33) |
P- 2 (33.33) |
P- 2 (50) |
|
| GFAP |
P- 7 (46.66) N- 2 (13.33) |
P- 6 (50) N- 1 (8.33) |
P- 5 (83.33) |
P- 1 (25) |
|
| Mib-1 | P- 10 (66.67) N- 1 (6.67) |
P- 6 (50) N- 3 (25) |
P- 2 (33.33) N- 2 (33.33) |
P- 2 (50) N- 1 (25) |
SU- Surgery, C–CH: Concurrent chemotherapy, RT- Radiotherapy, P-Positive, N-Negative, IDH: isocitrate dehydrogenase, MGMT: O6-methylguanine-DNA-methyltransferase; ATRX-alpha-thalassemia/mental retardation, X-linked; EGFR-epidermal growth factor receptor; GFAP- glial fibrillary acidic protein.
a
Out of 110 patients, n = 23- reports were not available for patients who were registered between 1995 and 2006, n = 36 -molecular analysis reports are available, while n = 51- molecular analysis were not done.
b
Astrocytoma, Glioblastoma, Glioma, Oligoastrocytoma, Oligodendroglioma & Pontine Glioma.
c
Medulloblastoma, Neuroblastoma.
d
Pineoblastoma.